STTK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.136

-63.28%

-0.140

-48.15%

-0.140

-41.67%

Estimates Revision

The market is revising No Change the revenue expectations for Shattuck Labs, Inc. (STTK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 59.78%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+59.78%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

Current: 2.860

Low

2.00

Averages

3.00

High

4.00

Current: 2.860

Low

2.00

Averages

3.00

High

4.00

Wedbush

NULL

Outperform

initiated

2025-09-08

Reason

Wedbush

Price Target

2025-09-08

initiated

NULL

Outperform

Reason

Wedbush initiated coverage of Shattuck Labs with an Outperform rating and $4 price target.

Leerink

Faisal Khurshid

Outperform

downgrade

$4 -> $2

2025-08-14

Reason

Leerink

Faisal Khurshid

Price Target

$4 -> $2

2025-08-14

downgrade

Outperform

Reason

Leerink analyst Faisal Khurshid lowered the firm's price target on Shattuck Labs to $2 from $4 and keeps an Outperform rating on the shares after the company reported Q2 earnings and provided a pipeline update including expected Phase 1 trial initiation for SL-325 this quarter. The firm expects this to be a pivotal moment for Shattuck's turnaround story as the company transitions to a clinical-stage company, and thinks this should support new interest in its first-in-class DR3 approach in inflammatory bowel disease. Leerink notes that its change in price target is driven by additional shares outstanding, with minimal change in its other key modeling assumptions.

HC Wainwright & Co.

Joseph Pantginis

Hold

Reiterates

n/a

2025-03-27

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

n/a

2025-03-27

Reiterates

Hold

Reason

Needham

Gil Blum

Hold

Reiterates

n/a

2025-03-27

Reason

Needham

Gil Blum

Price Target

n/a

2025-03-27

Reiterates

Hold

Reason

Leerink Partners

Faisal Khurshid

Buy

Initiates

2025-03-17

Reason

Leerink Partners

Faisal Khurshid

Price Target

2025-03-17

Initiates

Buy

Reason

Leerink analyst Faisal A. Khurshid initiated coverage of Shattuck Labs with an Outperform rating and $4 price target. The firm views Shattuck Labs' pivot into inflammatory bowel disease as an underappreciated opportunity, with lead program SL-325 representing a first-in-class approach with potential to improve upon related, clinically validated, TL1A targeting programs. The company expects key Phase 1 milestones for SL-325 over the next 1 year, and Leerink is optimistic that these can spur investor interest in the turnaround story.

Valuation Metrics

The current forward P/E ratio for Shattuck Labs Inc (STTK.O) is -5.80, compared to its 5-year average forward P/E of -5.12. For a more detailed relative valuation and DCF analysis to assess Shattuck Labs Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.12

Current PE

-5.80

Overvalued PE

1.66

Undervalued PE

-11.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.79

Current EV/EBITDA

-2.72

Overvalued EV/EBITDA

3.51

Undervalued EV/EBITDA

-9.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

427.87

Current PS

0.00

Overvalued PS

1466.99

Undervalued PS

-611.24

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 6464.33% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 6464.33% over the last month.

Sold

Bought

STTK News & Events

Events Timeline

No data

News

4.0

12-06NASDAQ.COM

Shattuck Labs (STTK) Price Target Raised by 33.33% to $4.08

4.0

12-01Benzinga

Analyst Upgrade Enhances Confidence in Shattuck's Next-Gen Inflammatory Bowel Disease Treatment

1.0

11-20Newsfilter

Shattuck Labs to Attend Investor Conferences Scheduled for December

People Also Watch

Frequently Asked Questions

What is Shattuck Labs Inc (STTK) stock price today?

The current price of STTK is 2.86 USD — it has decreased -7.74 % in the last trading day.

What is Shattuck Labs Inc (STTK)'s business?

Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

What is the price predicton of STTK Stock?

What is Shattuck Labs Inc (STTK)'s revenue for the last quarter?

Shattuck Labs Inc revenue for the last quarter amounts to 1,000K USD, decreased -66.63 % YoY.

What is Shattuck Labs Inc (STTK)'s earnings per share (EPS) for the last quarter?

Shattuck Labs Inc. EPS for the last quarter amounts to -0.14 USD, decreased -57.58 % YoY.

What changes have occurred in the market's expectations for Shattuck Labs Inc (STTK)'s fundamentals?

How many employees does Shattuck Labs Inc (STTK). have?

Shattuck Labs Inc (STTK) has 44 emplpoyees as of December 15 2025.

What is Shattuck Labs Inc (STTK) market cap?

Today STTK has the market capitalization of 196.17M USD.